Eczematous reactions due to angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers

被引:22
|
作者
Vena, Gino A. [1 ]
Cassano, Nicoletta [1 ]
Coco, Valeria [2 ]
De Simone, Clara [2 ]
机构
[1] Univ Bari, Dept Biomed Sci & Human Oncol, Unit Dermatol & Venereol, I-70124 Bari, Italy
[2] Univ Cattolica Sacro Cuore, Unit Dermatol, I-00168 Rome, Italy
关键词
Antihypertensive drugs; cutaneous adverse drug reactions; drug-induced dermatitis; eczema; hydrochlorothiazide; CAPTOPRIL; DRUG; SURVEILLANCE; BRADYKININ; IRBESARTAN; ERUPTION;
D O I
10.3109/08923973.2013.797992
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Cutaneous adverse drug reactions (ADRs) to antihypertensive drugs have been frequently reported. We describe a peculiar clinical pattern of cutaneous ADR, represented by an eczematous reaction induced by certain antihypertensive drugs that we observed in elderly patients. The case series consisted of 23 hypertensive patients aged 66-87 years; 19 of them were taking another drug in addition to the suspected antihypertensive medication and 15 were on polytherapy with three or more drugs to treat multiple comorbidities. The antihypertensive culprit agents were angiotensin-converting enzyme (ACE) inhibitors in 9 patients, ACE-inhibitors combined to hydrochlorothiazide (HCT) in 7 subjects, angiotensin II receptor blockers alone in 2 patients and associated with HCT in 5 cases. The cutaneous ADR was characterized by an eczematous rash that was generalized in 16 patients and localized in 7 cases, with predominant involvement of lower limbs. Such lesions developed after a latency of 4-30 months and were associated with moderate-to-severe itch, usually unresponsive to oral antihistamines. Histopathological diagnosis was available for 9 cases, confirming the presence of a spongiotic dermatitis with possible associated psoriasiform skin changes.
引用
收藏
页码:447 / 450
页数:4
相关论文
共 50 条
  • [41] Association between bone measures and use of angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers
    Holloway-Kew, Kara L.
    Betson, Amelia G.
    Anderson, Kara B.
    Gaston, James
    Kotowicz, Mark A.
    Liao, Wan-Hui
    Henneberg, Maciej
    Pasco, Julie A.
    ARCHIVES OF OSTEOPOROSIS, 2021, 16 (01)
  • [42] Combined treatment with angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers: A review of the current evidence
    Tsouli, SG
    Liberopoulos, EN
    Kiortsis, DN
    Mikhailidis, DP
    Elisaf, MS
    JOURNAL OF CARDIOVASCULAR PHARMACOLOGY AND THERAPEUTICS, 2006, 11 (01) : 1 - 15
  • [43] Angiotensin-converting enzyme inhibitors and angiotensin II type I receptor blockers after renal transplantation
    Morath, C.
    Schmied, B.
    Mehrabi, A.
    Weitz, J.
    Schmidt, J.
    Werner, J.
    Buchler, M. W.
    Morcos, M.
    Nawroth, P. P.
    Schwenger, V.
    Doehler, B.
    Opelz, G.
    Zeier, M.
    CLINICAL TRANSPLANTATION, 2009, 23 : 33 - 36
  • [44] Association between bone measures and use of angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers
    Kara L. Holloway-Kew
    Amelia G. Betson
    Kara B. Anderson
    James Gaston
    Mark A. Kotowicz
    Wan-Hui Liao
    Maciej Henneberg
    Julie A. Pasco
    Archives of Osteoporosis, 2021, 16
  • [45] Angiotensin-Converting Enzyme 2 and Antihypertensives (Angiotensin Receptor Blockers and Angiotensin-Converting Enzyme Inhibitors) in Coronavirus Disease 201p
    Sanchis-Gomar, Fabian
    Lavie, Carl J.
    Perez-Quilis, Carme
    Henry, Brandon M.
    Lippi, Giuseppe
    MAYO CLINIC PROCEEDINGS, 2020, 95 (06) : 1222 - 1230
  • [46] In reply - Angiotensin-Converting Enzyme 2 and the Resolution of Inflammation: In Support of Continuation of Prescribed Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers
    Sanchis-Gomar, Fabian
    Lavie, Carl J.
    Perez-Quilis, Carme
    Henry, Brandon M.
    Lippi, Giuseppe
    MAYO CLINIC PROCEEDINGS, 2020, 95 (07) : 1553 - 1556
  • [47] Renin–angiotensin–aldosterone system blockade and renal protection: angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers?
    L. M. Ruilope
    Acta Diabetologica, 2005, 42 : s33 - s41
  • [48] The Fetal Safety of Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers
    Moretti, Myla E.
    Caprara, Daniela
    Drehuta, Irina
    Yeung, Emily
    Cheung, Stefanie
    Federico, Lisa
    Koren, Gideon
    OBSTETRICS AND GYNECOLOGY INTERNATIONAL, 2012, 2012
  • [49] The Fetal Safety of Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers
    Moretti, M. E.
    Caprara, D.
    Drehuta, I
    Yeung, E.
    Cheung, S.
    Federico, L.
    Koren, G.
    BIRTH DEFECTS RESEARCH PART A-CLINICAL AND MOLECULAR TERATOLOGY, 2010, 88 (05) : 439 - 439
  • [50] Effects of angiotensin receptor blockers and angiotensin-converting enzyme inhibitors on COVID-19
    Xiao-Long Li
    Tao Li
    Qi-Cong Du
    Li Yang
    Kun-Lun He
    World Journal of Clinical Cases, 2021, 9 (20) : 5462 - 5469